Background: Intramuscular (IM) sustained release antiretroviral (ARV) nano-formulations (NFs) may provide pharmacological options to simplify regimens, reduce drug costs and improve adherence. Studies are currently on-going with injectable preparations for pre-exposure prophylaxis and treatment. The aim of this study was to simulate the pharmacokinetics (PK) of IM sustained release NFs using physiologically based pharmacokinetic (PBPK) modelling. Existing ARVs were assessed for compatibility and theoretical target dose and release rate for once weekly and/or monthly administration formats were identified. Methodology: In vitro or population PK data for 8 ARVs were integrated into PBPK models and ARV PK was simulated for 100 individuals using MATLAB, R2013b. The models included mathematical descriptions of covariance between demographics and tissue size, expression of metabolic enzymes and processes regulating absorption, distribution and elimination, which are drug-specific. The models were validated against clinical data for oral administration at standard regimens but rilpivirine (RPV) was also validated against available PK data for the 600 mg IM depot. Validated PBPK models were used for the prediction of PK following IM administration of theoretical sustained release NFs. ARV dose and release rate were optimised to obtain Ctrough values above the protein binding corrected IC95 (PBIC95) or clinical cut-offs obtained from literature sources. Results: The simulated PK parameters for oral administration were in agreement with previously published clinical data. For validation against the existing formulation, simulated 600 mg IM RPV, mean values for AUC were 87.7 vs. 84.0 ng.h/mL, Cmax 91.7 vs. 96.7 ng/mL and Ctrough 13.3 vs. 15.7 ng/mL for simulated versus observed data with a predicted release rate of 0.0011 /h for the existing formulation. The table gives simulated PK for IM administration and a prediction of the optimal ARV dose and release rate combination. Dolutegravir, efavirenz, emtricitabine, raltegravir, tenofovir and RPV were predicted to be the suitable candidates for monthly IM formats. Conclusions: PBPK models were used to estimate optimal dose and release rate and may be useful to inform target product profiles for sustainedrelease NFs. Candidates with the potential for reformulation into an IM injection were identified, providing the technological complexities associated with reformulation can be overcome for these agents.